Presentation is loading. Please wait.

Presentation is loading. Please wait.

The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma  Yasuhiro Tsutani, MD, PhD, Yoshihiro.

Published by우선 묘 Modified over 5 years ago

Similar presentations

Presentation on theme: "The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma  Yasuhiro Tsutani, MD, PhD, Yoshihiro."— Presentation transcript:

1 The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma  Yasuhiro Tsutani, MD, PhD, Yoshihiro Miyata, MD, PhD, Takahiro Mimae, MD, PhD, Kei Kushitani, MD, PhD, Yukio Takeshima, MD, PhD, Masahiro Yoshimura, MD, PhD, Morihito Okada, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 146, Issue 3, Pages (September 2013) DOI: /j.jtcvs Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 ROC-AUC values of total tumor and invasive component sizes used for predicting pathologic malignant behavior (LY, V, or PL). The invasive component size predicted the pathologic malignant behavior better than the total tumor size. CI, Confidence interval; AUC, area under the curve; LY, lymphatic invasion; V, vascular invasion; PL, pleural invasion. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 There were significant differences in RFS among patients with an invasive component size of 0.5 cm or smaller (5-year RFS rate, 96.6%), 0.5 to 2.0 cm (5-year RFS rate, 70.6%), and larger than 2.0 cm (5-year RFS rate, 62.2%). RFS, Recurrence-free survival. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 A, There were no differences in RFS between patients who received adjuvant chemotherapy and those who did not in the group with an invasive component size of 0.5 cm or less (5-year RFS, 90.0% vs 97.1%; P = .29). B, There were no differences in RFS between patients who received adjuvant chemotherapy and those who did not in the group with an invasive component size of 0.5 to 2.0 cm (5-year RFS, 77.9% vs 69.4%; P = .50). C, There was a significant difference in RFS between patients who received adjuvant chemotherapy and those who did not in the group with an invasive component size of larger than 2.0 cm (5-year RFS, 78.6% vs 53.1%; P = .009). RFS, Recurrence-free survival. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2013 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma  Yasuhiro Tsutani, MD, PhD, Yoshihiro."

Similar presentations

Blood lactate level during extracorporeal life support as a surrogate marker for survival  Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,

Blood lactate level during extracorporeal life support as a surrogate marker for survival  Sung Jun Park, MD, Sang-pil Kim, MD, PhD, Joon Bum Kim, MD,
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.

Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant.
Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Lost in translation The Journal of Thoracic and Cardiovascular Surgery

Lost in translation The Journal of Thoracic and Cardiovascular Surgery
Manuel J. Antunes, MD, PhD, DSc 

Manuel J. Antunes, MD, PhD, DSc 
Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,
The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street?  Frank C. Detterbeck, MD  The Journal of Thoracic and Cardiovascular.
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD 
Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies.

Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies.
Pleomorphic carcinoma of the lung: A surgical outcome

Pleomorphic carcinoma of the lung: A surgical outcome
Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes  Ruben Pio, PharmD, PhD, Jackeline.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes  Ruben Pio, PharmD, PhD, Jackeline.
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Similar presentations

Ads by Google